Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name HOXA11-AS
   Synonyms HOXA11-AS, HOXA-AS5, HOXA11-AS1, HOXA11AS, HOXA11S, NCRNA00076
   Region GRCh38_7:27184518-27189293    Sequence
   Ensembl ENSG00000240990
   RefSeq NR_002795
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name lung adenocarcinoma
   ICD-0-3 C34  M8140/3
   Methods DNA methylation etc.
   Sample cell lines
   Expression Pattern differential expression
   Function Description

competing endogenous RNA network analysis inferred that lncRNA ENSG00000240990 competed with HOXA10 to absorb hsa-let-7a/b/f/g-5p and affected patient prognosis in LUAD. Last but not least, by integrating target information of miRNA we also provided a new perspective for the discovery of potential small molecule drugs. Some small molecule drugs, such as Enoxacin and Etoposide, regulated the competitive relations of lncRNA-PCG pairs by influencing the expression of hsa-let-7a/b/f/g-5p, which provided novel clues for LUAD treatment. Therefore, we combined the information that was provided by SM2miR [67] with the module to infer potential small molecule drugs for LUAD treatment. In the ceRNA module, some potential drugs could up-regulate the hsa-let-7a/b/f/g-5p expression and further down-regulate the expression of related lncRNAs/PCGs and contribute to the treatment of LUAD ((Figure10)).

   Pubmed ID 29069717
   Year 2017
   Title Integrated analysis of dosage effect lncRNAs in lung adenocarcinoma based on comprehensive network.
   External Links
   Links for  HOXA11-AS GenBank       HGNC       lncrnadb       Noncode
   Links for  lung adenocarcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.